German company is a provider of targeted drug rescue program intended to involve pharmaceutical research and development.
Exciva has raised €60M across 2 funding rounds from 10 investors, most recently a Series B round in Jan 2026. Based in Heidelberg, Germany; active in Healthtech. Data as of 6 Aug 2026.
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2026-01-20 | Series B | €51M | Carma Fund,Andera Partners,EQT Life Sciences,Fountain Healthcare Partners,Gimv,LBBW VC+2 more | View deal → |
| 2021-10-26 | Series A | €9.0M | Andera Partners,Cure8,LBBW Venture Capital GmbH | View deal → |
